ClinicalTrials.gg
RecruitingNCT07220564VOYAGER2Updated Sep 18, 2026

A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

A Phase 1 interventional study of NNC0442-0344 A in Haemophilia A, sponsored by Novo Nordisk A/S. Recruiting at 33 sites in 12 countries. Open to male participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 92 studies in Hemophilia A by Novo Nordisk A/S — 8 open to participants now, 12 under way, 5 of them phase 3. Hemophilia A · Novo Nordisk A/S.

Planned enrollment
36th of 59
30 · median 38
Started
2025
with 3 others
Phase 1
27 of 92
1 open now
Primary completion
2027-02
later than 6 of 11 live
Registered
89th of 92
by date

Among the 92 studies in Hemophilia A by Novo Nordisk A/S, this one is the 36th largest by planned enrollment of the 59 interventional ones that give a count, is one of 4 that started in 2025, is one of 27 in phase 1, reaches primary completion later than 6 of the 11 other live ones, and was the 89th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

8 of the 92 studies in Hemophilia A by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 64 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Hemophilia A by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study will test how different doses of study medicine (Inno8) work in the bodies of people with haemophilia A. The purpose of the study is to see if Inno8 is safe to use for people with haemophilia A. The study medicine is a new medicine that cannot yet be prescribed by doctors. The study will last for about 11 weeks.

03

Conditions studied

  • Haemophilia A

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male
  • Age 18-64 years (both inclusive) at the time of signing the .
  • Body weight greater than or equal to (≥) 45 kilograms (kgs).
  • Diagnosis of congenital haemophilia A with factor VIII (FVIII) activity less than or equal to (≤) 15 percentage (%) with or without FVIII inhibitors, based on medical records.

Exclusion criteria

Exclusion Criteria:

  • Current or prior exposure to any prophylactic treatment for haemophilia A within 5 half-lives of the medicinal product by the time of screening.
  • ≥30.0 kilogram per square meter (kg/m\^2).
  • Increased risk of thrombosis, e.g. known history of personal or first-degree relative(s) with unprovoked deep vein thrombosis.
  • Any clinical signs or established diagnosis of venous or arterial thromboembolic disease.
  • Any known coagulation disorders other than haemophilia A.
  • Ongoing or planned immune tolerance induction therapy.
  • Presence of gastrointestinal disorders potentially affecting absorption of drugs and/or nutrients, as judged by the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Participants will receive oral dose of NNC0442-0344 A.

    Drug: NNC0442-0344 A

  • Experimental
    Cohort 2

    Participants will receive oral dose of NNC0442-0344 A.

    Drug: NNC0442-0344 A

  • Experimental
    Cohort 3

    Participants will receive oral dose of NNC0442-0344 A.

    Drug: NNC0442-0344 A

Interventions

  • NNC0442-0344 A will be administered orally.

    Also known as: Inno8

06

What researchers measure

Primary outcomes

  1. Number of treatment emergent adverse events

    Measured as count of events.

    Time frame: From time of dosing (Day 1) to end of follow-up (Day 46)

Secondary outcomes

  1. Change in D-dimer

    Measured as absolute and percentage (%).

    Time frame: From time of dosing (Day 1) to end of follow-up (Day 46)

  2. Change in prothrombin fragment 1 and 2

    Measured as absolute and %.

    Time frame: From time of dosing (Day 1) to end of follow-up (Day 46)

  3. Change in fibrinogen

    Measured as absolute and %.

    Time frame: From time of dosing (Day 1) to end of follow-up (Day 46)

  4. Change in platelets

    Measured as absolute and %.

    Time frame: From time of dosing (Day 1) to end of follow-up (Day 46)

  5. Occurrence of anti-Inno8 antibodies

    Measured as count.

    Time frame: From time of dosing (Day 1) to end of follow-up (Day 46)

  6. Cmax: the maximum concentration of Inno8 after multiple doses

    Measured as nanograms per millilitre (ng/mL).

    Time frame: From Day 10 to Day 11

  7. Tmax: the time to Cmax after last multiple dose

    Measured as hours.

    Time frame: From day 10 to Day 11

  8. Tmax: the time to Cmax after first dose

    Measured as hours.

    Time frame: From Day 1 to Day 2

  9. AUC: the area under the Inno8 concentration-time curve in the dosing interval after multiple doses

    Measured as nanograms\*day per millilitre (ng\*day/mL).

    Time frame: From Day 10 to Day 11

  10. Maximum thrombin generation (peak height)

    Measured as nanomolar (nM).

    Time frame: From Day 10 to Day 11

07

Study locations

25 of 33 sites recruiting
  • UC Denver Hemoph & Thrombo Ctr
    Aurora, Colorado 80045, United States
    Recruiting
  • Indiana Hemophilia-Thromb Ctr
    Indianapolis, Indiana 46260, United States
    Recruiting
  • University of Iowa_Iowa City
    Iowa City, Iowa 52242, United States
    Recruiting
  • Penn State MS Hershey Med Ctr
    Hershey, Pennsylvania 17033-2360, United States
    Recruiting
  • St Christopher Hosp for Child
    Philadelphia, Pennsylvania 19134, United States
    Recruiting
  • Universitätsklinik für Innere Medizin V
    Innsbruck, 6020, Austria
    Recruiting
  • AKH - Klin. Abt. f. Haematologie u. Haemostaseologie
    Vienna, 1090, Austria
    Recruiting
  • Cliniques universitaires Saint-Luc
    Brussels, 1200, Belgium
    Not yet recruiting
  • HCL - HOPITAL LOUIS PRADEL - Unité d'hémostase Clinique
    Bron, 69500, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Vivantes Netzwerk für Gesundheit GmbH - Vivantes Klinikum im Friedrichshain
    Berlin, 10249, Germany
    Recruiting
  • Universitätsklinikum Bonn - Institut für Experimentelle Hämatologie
    Bonn, 53127, Germany
    Not yet recruiting
  • Medizinische Hochschule Hannover - Hämatologie, Hämostaseologie, Onkologie
    Hanover, 30625, Germany
    Recruiting
  • AOU Careggi Firenze
    Florence, 50134, Italy
    Recruiting
  • Azienda Ospedaliera Universitaria Federico II di Napoli
    Naples, 80131, Italy
    Recruiting
  • Uniwersytecki Szpital Kliniczny w Bialymstoku
    Bialystok, 15-276, Poland
    Recruiting
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-214, Poland
    Recruiting
  • Samodzielny Publiczny Szpital Kliniczny im. Andrzeja Mielęckiego Slaskiego Uniwersytetu Medycznego w Katowicach
    Katowice, 40-032, Poland
    Not yet recruiting
  • Uniwersytecki Szpital Kliniczny nr 1 Klinika Hematoonkologii i Transplantacji Szpiku
    Lublin, 20-081, Poland
    Not yet recruiting
  • Uniwersytecki Szpital Kliniczny W Poznaniu
    Poznan, 60-569, Poland
    Not yet recruiting
  • Instytut Hematologii i Transfuzjologii
    Warsaw, 02-776, Poland
    Recruiting
  • ULS De Santo António, E.P.E. _H.Santo António_ Imunohemoterapia
    Porto, 4050-342, Portugal
    Recruiting
  • ULS São João, E.P.E._H.São João_Imunohemoterapia
    Porto, 4200-319, Portugal
    Recruiting
  • Hospital Vall d'Hebron
    Barcelona, 08035, Spain
    Recruiting
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
    Recruiting
  • Hospital Regional Universitario de Málaga
    Málaga, 29010, Spain
    Recruiting
  • Hospital Clinico Universitario de Salamanca
    Salamanca, 37007, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital La Fe_Hemostasia y Trombosis
    Valencia, 46026, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Skåne US - Koagulationsmottagning
    Malmö, 214 28, Sweden
    Recruiting
  • KS Solna - Koagulationsmottagningen
    Solna, 171 64, Sweden
    Recruiting
  • Zentrum für Labormedizin
    Sankt Gallen, 9008, Switzerland
    Recruiting
  • Queen Elizabeth Hospital, Birmingham - Haemophilia
    Birmingham, B15 2TH, United Kingdom
    Recruiting
  • Royal Free Hospital - Haemophilia
    London, NW3 2QG, United Kingdom
    Recruiting
  • Royal Hallamshire Hospital
    Sheffield, S10 2JF, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Feb 2027, 15 months after the start.

Of 37 industry-sponsored phase 1 interventional studies under Hemophilia A, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 15 months is above that.

Counting every sponsor, half of 46 studies reached it within 13 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2025
First posted
Oct 24, 2025
StartActual
Oct 23, 2025
Primary completionEst.
Feb 5, 2027
CompletionEst.
Feb 5, 2027
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07220564
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 24, 2025
Start date
Oct 23, 2025
Primary completion
Feb 5, 2027 (estimated)
Completion
Feb 5, 2027 (estimated)
Last update
Sep 18, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NNC0442-0344

Start the discussion